FDA officials are pushing for long-term follow-up of patients with autoimmune diseases who receive CAR-T therapy. They advise drug developers to study the long-term effects of this therapy in autoimmune conditions. They fear that CAR-T therapy could bring risks for these patients. CAR-T therapy is being tested for autoimmune diseases such as systemic lupus erythematosus, myasthenia gravis or multiple sclerosis. Patients after CAR-T therapy need long-term monitoring to detect delayed side effects, such as fatigue, changes in immune functions or neurological symptoms. Some cancer patients remain in complete remission for more than 9 or 12 years after therapy.